RNA Editing MarketSize, Share & Industry Analysis, 2026-2034By TechnologyBy Edit TypeBy Delivery MethodBy OfferingBy Therapeutic AreaBy Target MechanismBy Development StageBy Route of AdministrationBy ApplicationBy End User
Full title & scope — all 10 axes with their segments
RNA Editing Market Size, Share & Industry Analysis, By Technology (ADAR-based RNA Editing, CRISPR-based RNA Editing, APOBEC-based RNA Editing, RNA Exon Editing, Chemical and Synthetic Editing Platforms, Epitranscriptomic Editing), By Edit Type (Adenosine-to-Inosine, Cytidine-to-Uridine, Exon Replacement, RNA Base Modification, Splicing Modulation), By Delivery Method (Lipid Nanoparticles, Adeno-Associated Virus Vectors, GalNAc Conjugates, Lentiviral Vectors, Electroporation, Other Non-viral Methods), By Offering (Therapeutic Candidates and Programs, Reagents and Kits, Instruments and Platforms, Software and Bioinformatics, Services), By Therapeutic Area (Rare Genetic Disorders, Neurological Disorders, Oncology, Ophthalmic Disorders, Cardiovascular and Metabolic Disorders, Infectious Diseases, Liver Diseases), By Target Mechanism (Correction of Pathogenic Point Mutations, Protein Upregulation, Protein Modulation, Start Codon and Stop Codon Editing, Post-translational Modification Site Editing, Splice Site Editing), By Development Stage (Discovery and Research, Preclinical, Phase I, Phase II, Phase III and Beyond), By Route of Administration (Intravenous, Subcutaneous, Intrathecal, Intravitreal, Intramuscular, Intracerebroventricular), By Application (Therapeutics Development, Drug Discovery and Target Validation, Basic and Translational Research, Diagnostics and Biomarker Development, Agricultural and Industrial Biotechnology), By End User (Biotechnology Companies, Pharmaceutical Companies, Academic and Research Institutes, Contract Research and Manufacturing Organizations, Hospitals and Specialty Clinics), and Regional Forecast, 2026-2034
Last Updated: Oct 27, 2026Report ID: CDI-248811
TOC
Full table of contents for the published report, chapter by chapter.
Full chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
1.1Strategic Imperatives
1.2Definition
1.3RNA Editing Comparison By Segments
Chapter 2.Premium Insights
2.1Top 3 Trends to Watch
2.2Top 3 Strategies Followed by Major Players
2.3Top 3 Predictions by Contrive Datum Insights
2.4Top Investment Pockets
2.4.1Market Attractiveness Analysis, By Technology
2.4.2Market Attractiveness Analysis, By Edit Type
2.4.3Market Attractiveness Analysis, By Delivery Method
2.4.4Market Attractiveness Analysis, By Offering
2.4.5Market Attractiveness Analysis, By Therapeutic Area
2.4.6Market Attractiveness Analysis, By Target Mechanism
2.4.7Market Attractiveness Analysis, By Development Stage
2.4.8Market Attractiveness Analysis, By Route of Administration
2.4.9Market Attractiveness Analysis, By Application
2.4.10Market Attractiveness Analysis, By End User
2.5Key Market Participants — Intensity Mapping
2.6Insights From Primary Respondents
Chapter 3.Market Definition
Chapter 4.Research Methodology
4.1Research Approach
4.1.1Research Programs / Design
4.1.2Market Size Estimation
4.2Data Sources
4.2.1Secondary Sources
4.2.1.1Preliminary Data Mining
4.2.2Primary Sources
4.2.2.1Statistical Model
4.2.2.2Data Triangulation
4.2.2.3Research Objective
4.3Flow Of Methodology
4.4Top-Down / Bottom-Up Approach
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
6.1Market Focus & Value Proposition
6.1.1Target Customers, Priority Markets, and Core Value Proposition
6.1.2Product Differentiation and Positioning Logic
6.2Commercial Model & Pricing Strategy
6.2.1Pricing Approach and Value Capture
6.2.2Contracting, Bundling, and Monetization Framework
6.3Channels, Sales & Partnerships
6.3.1Direct and Indirect Channel Strategy
6.3.2Sales Execution Model and Strategic Partnerships
6.4Marketing, Launch & Execution Roadmap
6.4.1Marketing and Demand Generation Approach
6.4.2Launch Sequencing and Rollout Plan
6.5Operational Readiness & Governance KPIs
6.5.1Supply Chain and Operational Preparedness
6.5.2Regulatory Considerations, Risks, and Performance Tracking
Chapter 7.Market Trends, Strategy & Dynamics
7.1Trends Overview
7.2Strategic Overview
7.3Market Drivers
7.4Market Restraints
7.5Market Opportunities
7.6Market Challenges
7.7Impact Analysis of Market Dynamics
Chapter 8.Porter's Five Forces
8.1Bargaining Power of Suppliers
8.2Bargaining Power of Buyers
8.3Threat of New Entrants
8.4Threat of Substitutes
8.5Competitive Rivalry
Chapter 9.PESTEL Analysis
9.1Political
9.2Economic
9.3Social
9.4Technological
9.5Environmental
9.6Legal
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
12.1Macro-Economic Factors Overview
12.2Forecast Factors — Relevance and Impact
Chapter 13.Market Cost Analysis
13.1Key Raw Materials Analysis
13.1.1Key Raw Materials
13.1.2Price Trend of Key Raw Materials
13.1.3Key Suppliers of Raw Materials
13.1.4Market Concentration Rate of Raw Materials
13.1.5Raw Materials
13.1.6Labor Cost
Chapter 14.Market Supply-Side Analysis
14.1Raw Materials
14.2Price Trends
14.3Industry Chain
14.4Raw Materials Sourcing
14.5Raw Materials Sources of Major Manufacturers
14.6Downstream Buyers
Chapter 15.Global RNA Editing Market Size & Projections, 2020–2034, Revenue (USD Billion)
15.1Global RNA Editing Market Size — Total
15.2Market Size, by Segment (By Technology, By Edit Type, By Delivery Method, By Offering, By Therapeutic Area, By Target Mechanism, By Development Stage, By Route of Administration, By Application, By End User)
Chapter 16.Global RNA Editing Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
16.1Introduction
16.2Global RNA Editing Market Size, By Technology, 2020–2034, Revenue (USD Billion)
16.3Global RNA Editing Market Share, By Technology (%)
16.3.1ADAR-based RNA Editing
16.3.1.1Market Size, By ADAR-based RNA Editing, 2020–2034, Revenue (USD Billion)
16.3.1.2ADAR-based RNA Editing Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
16.3.1.3ADAR-based RNA Editing Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
16.3.1.4ADAR-based RNA Editing Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
16.3.1.5ADAR-based RNA Editing Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
16.3.1.6ADAR-based RNA Editing Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
16.3.1.7ADAR-based RNA Editing Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
16.3.1.8ADAR-based RNA Editing Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
16.3.1.9ADAR-based RNA Editing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
16.3.1.10ADAR-based RNA Editing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
16.3.2CRISPR-based RNA Editing
16.3.3APOBEC-based RNA Editing (C-to-U)
16.3.4RNA Exon Editing (Trans-Splicing)
16.3.5Chemical and Synthetic Editing Platforms
16.3.6Epitranscriptomic Editing (m6A and Pseudouridine)
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 16.3.1 (ADAR-based RNA Editing).
Chapter 17.Global RNA Editing Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
17.1Introduction
17.2Global RNA Editing Market Size, By Edit Type, 2020–2034, Revenue (USD Billion)
17.3Global RNA Editing Market Share, By Edit Type (%)
17.3.1Adenosine-to-Inosine (A-to-I)
17.3.1.1Market Size, By Adenosine-to-Inosine (A-to-I), 2020–2034, Revenue (USD Billion)
17.3.1.2Adenosine-to-Inosine (A-to-I) Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
17.3.1.3Adenosine-to-Inosine (A-to-I) Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
17.3.1.4Adenosine-to-Inosine (A-to-I) Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
17.3.1.5Adenosine-to-Inosine (A-to-I) Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
17.3.1.6Adenosine-to-Inosine (A-to-I) Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
17.3.1.7Adenosine-to-Inosine (A-to-I) Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
17.3.1.8Adenosine-to-Inosine (A-to-I) Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
17.3.1.9Adenosine-to-Inosine (A-to-I) Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
17.3.1.10Adenosine-to-Inosine (A-to-I) Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
17.3.2Cytidine-to-Uridine (C-to-U)
17.3.3Exon Replacement
17.3.4RNA Base Modification
17.3.5Splicing Modulation
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 17.3.1 (Adenosine-to-Inosine (A-to-I)).
Chapter 18.Global RNA Editing Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
18.1Introduction
18.2Global RNA Editing Market Size, By Delivery Method, 2020–2034, Revenue (USD Billion)
18.3Global RNA Editing Market Share, By Delivery Method (%)
18.3.1Lipid Nanoparticles
18.3.1.1Market Size, By Lipid Nanoparticles, 2020–2034, Revenue (USD Billion)
18.3.1.2Lipid Nanoparticles Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
18.3.1.3Lipid Nanoparticles Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
18.3.1.4Lipid Nanoparticles Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
18.3.1.5Lipid Nanoparticles Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
18.3.1.6Lipid Nanoparticles Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
18.3.1.7Lipid Nanoparticles Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
18.3.1.8Lipid Nanoparticles Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
18.3.1.9Lipid Nanoparticles Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
18.3.1.10Lipid Nanoparticles Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
18.3.2Adeno-Associated Virus Vectors
18.3.3GalNAc Conjugates
18.3.4Lentiviral Vectors
18.3.5Electroporation
18.3.6Other Non-viral Methods
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 18.3.1 (Lipid Nanoparticles).
Chapter 19.Global RNA Editing Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
19.1Introduction
19.2Global RNA Editing Market Size, By Offering, 2020–2034, Revenue (USD Billion)
19.3Global RNA Editing Market Share, By Offering (%)
19.3.1Therapeutic Candidates and Programs
19.3.1.1Market Size, By Therapeutic Candidates and Programs, 2020–2034, Revenue (USD Billion)
19.3.1.2Therapeutic Candidates and Programs Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
19.3.1.3Therapeutic Candidates and Programs Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
19.3.1.4Therapeutic Candidates and Programs Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
19.3.1.5Therapeutic Candidates and Programs Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
19.3.1.6Therapeutic Candidates and Programs Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
19.3.1.7Therapeutic Candidates and Programs Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
19.3.1.8Therapeutic Candidates and Programs Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
19.3.1.9Therapeutic Candidates and Programs Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
19.3.1.10Therapeutic Candidates and Programs Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
19.3.2Reagents and Kits
19.3.3Instruments and Platforms
19.3.4Software and Bioinformatics
19.3.5Services
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 19.3.1 (Therapeutic Candidates and Programs).
Chapter 20.Global RNA Editing Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
20.1Introduction
20.2Global RNA Editing Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
20.3Global RNA Editing Market Share, By Therapeutic Area (%)
20.3.1Rare Genetic Disorders
20.3.1.1Market Size, By Rare Genetic Disorders, 2020–2034, Revenue (USD Billion)
20.3.1.2Rare Genetic Disorders Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
20.3.1.3Rare Genetic Disorders Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
20.3.1.4Rare Genetic Disorders Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
20.3.1.5Rare Genetic Disorders Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
20.3.1.6Rare Genetic Disorders Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
20.3.1.7Rare Genetic Disorders Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
20.3.1.8Rare Genetic Disorders Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
20.3.1.9Rare Genetic Disorders Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
20.3.1.10Rare Genetic Disorders Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
20.3.2Neurological Disorders
20.3.3Oncology
20.3.4Ophthalmic Disorders
20.3.5Cardiovascular and Metabolic Disorders
20.3.6Infectious Diseases
20.3.7Liver Diseases
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 20.3.1 (Rare Genetic Disorders).
Chapter 21.Global RNA Editing Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
21.1Introduction
21.2Global RNA Editing Market Size, By Target Mechanism, 2020–2034, Revenue (USD Billion)
21.3Global RNA Editing Market Share, By Target Mechanism (%)
21.3.1Correction of Pathogenic Point Mutations
21.3.1.1Market Size, By Correction of Pathogenic Point Mutations, 2020–2034, Revenue (USD Billion)
21.3.1.2Correction of Pathogenic Point Mutations Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
21.3.1.3Correction of Pathogenic Point Mutations Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
21.3.1.4Correction of Pathogenic Point Mutations Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
21.3.1.5Correction of Pathogenic Point Mutations Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
21.3.1.6Correction of Pathogenic Point Mutations Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
21.3.1.7Correction of Pathogenic Point Mutations Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
21.3.1.8Correction of Pathogenic Point Mutations Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
21.3.1.9Correction of Pathogenic Point Mutations Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
21.3.1.10Correction of Pathogenic Point Mutations Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
21.3.2Protein Upregulation
21.3.3Protein Modulation
21.3.4Start Codon and Stop Codon Editing
21.3.5Post-translational Modification Site Editing
21.3.6Splice Site Editing
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 21.3.1 (Correction of Pathogenic Point Mutations).
Chapter 22.Global RNA Editing Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
22.1Introduction
22.2Global RNA Editing Market Size, By Development Stage, 2020–2034, Revenue (USD Billion)
22.3Global RNA Editing Market Share, By Development Stage (%)
22.3.1Discovery and Research
22.3.1.1Market Size, By Discovery and Research, 2020–2034, Revenue (USD Billion)
22.3.1.2Discovery and Research Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
22.3.1.3Discovery and Research Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
22.3.1.4Discovery and Research Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
22.3.1.5Discovery and Research Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
22.3.1.6Discovery and Research Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
22.3.1.7Discovery and Research Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
22.3.1.8Discovery and Research Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
22.3.1.9Discovery and Research Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
22.3.1.10Discovery and Research Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
22.3.2Preclinical
22.3.3Phase I
22.3.4Phase II
22.3.5Phase III and Beyond
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 22.3.1 (Discovery and Research).
Chapter 23.Global RNA Editing Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
23.1Introduction
23.2Global RNA Editing Market Size, By Route of Administration, 2020–2034, Revenue (USD Billion)
23.3Global RNA Editing Market Share, By Route of Administration (%)
23.3.1Intravenous
23.3.1.1Market Size, By Intravenous, 2020–2034, Revenue (USD Billion)
23.3.1.2Intravenous Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
23.3.1.3Intravenous Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
23.3.1.4Intravenous Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
23.3.1.5Intravenous Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
23.3.1.6Intravenous Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
23.3.1.7Intravenous Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
23.3.1.8Intravenous Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
23.3.1.9Intravenous Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
23.3.1.10Intravenous Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
23.3.2Subcutaneous
23.3.3Intrathecal
23.3.4Intravitreal
23.3.5Intramuscular
23.3.6Intracerebroventricular
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 23.3.1 (Intravenous).
Chapter 24.Global RNA Editing Market Overview, By Application, 2020–2034, Revenue (USD Billion)
24.1Introduction
24.2Global RNA Editing Market Size, By Application, 2020–2034, Revenue (USD Billion)
24.3Global RNA Editing Market Share, By Application (%)
24.3.1Therapeutics Development
24.3.1.1Market Size, By Therapeutics Development, 2020–2034, Revenue (USD Billion)
24.3.1.2Therapeutics Development Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
24.3.1.3Therapeutics Development Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
24.3.1.4Therapeutics Development Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
24.3.1.5Therapeutics Development Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
24.3.1.6Therapeutics Development Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
24.3.1.7Therapeutics Development Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
24.3.1.8Therapeutics Development Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
24.3.1.9Therapeutics Development Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
24.3.1.10Therapeutics Development Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
24.3.2Drug Discovery and Target Validation
24.3.3Basic and Translational Research
24.3.4Diagnostics and Biomarker Development
24.3.5Agricultural and Industrial Biotechnology
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 24.3.1 (Therapeutics Development).
Chapter 25.Global RNA Editing Market Overview, By End User, 2020–2034, Revenue (USD Billion)
25.1Introduction
25.2Global RNA Editing Market Size, By End User, 2020–2034, Revenue (USD Billion)
25.3Global RNA Editing Market Share, By End User (%)
25.3.1Biotechnology Companies
25.3.1.1Market Size, By Biotechnology Companies, 2020–2034, Revenue (USD Billion)
25.3.1.2Biotechnology Companies Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
25.3.1.3Biotechnology Companies Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
25.3.1.4Biotechnology Companies Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
25.3.1.5Biotechnology Companies Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
25.3.1.6Biotechnology Companies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
25.3.1.7Biotechnology Companies Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
25.3.1.8Biotechnology Companies Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
25.3.1.9Biotechnology Companies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
25.3.1.10Biotechnology Companies Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
25.3.2Pharmaceutical Companies
25.3.3Academic and Research Institutes
25.3.4Contract Research and Manufacturing Organizations
25.3.5Hospitals and Specialty Clinics
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 25.3.1 (Biotechnology Companies).
Chapter 26.Global RNA Editing Market Size — Segment Comparison
Chapter 27.Global RNA Editing Geography Overview, 2020–2034, Revenue (USD Billion)
27.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
27.2Share, By Geography, 2020–2034 (%)
27.3Share, By Geography Analysis, 2025, Market Share and CAGR
27.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Chapter 28.North America RNA Editing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
28.1Overview, 2020–2034
28.2Size and Projections, 2020–2034, Revenue (USD Billion)
28.2.1By Technology, 2020–2034
28.2.2By Edit Type, 2020–2034
28.2.3By Delivery Method, 2020–2034
28.2.4By Offering, 2020–2034
28.2.5By Therapeutic Area, 2020–2034
28.2.6By Target Mechanism, 2020–2034
28.2.7By Development Stage, 2020–2034
28.2.8By Route of Administration, 2020–2034
28.2.9By Application, 2020–2034
28.2.10By End User, 2020–2034
28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
28.3.1US
28.3.1.1US — Key Country Dynamics
28.3.1.2US — Regulatory Framework
28.3.1.3US — Competitive Scenario
28.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
28.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
28.3.1.6US Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
28.3.1.7US Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
28.3.1.8US Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
28.3.1.9US Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
28.3.1.10US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
28.3.1.11US Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
28.3.1.12US Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
28.3.1.13US Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
28.3.1.14US Market Overview, By Application, 2020–2034, Revenue (USD Billion)
28.3.1.15US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
28.3.2Canada
28.3.3Mexico
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 28.3.1 (US).
Chapter 29.Europe RNA Editing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
29.1Overview, 2020–2034
29.2Size and Projections, 2020–2034, Revenue (USD Billion)
29.2.1By Technology, 2020–2034
29.2.2By Edit Type, 2020–2034
29.2.3By Delivery Method, 2020–2034
29.2.4By Offering, 2020–2034
29.2.5By Therapeutic Area, 2020–2034
29.2.6By Target Mechanism, 2020–2034
29.2.7By Development Stage, 2020–2034
29.2.8By Route of Administration, 2020–2034
29.2.9By Application, 2020–2034
29.2.10By End User, 2020–2034
29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
29.3.1Germany
29.3.1.1Germany — Key Country Dynamics
29.3.1.2Germany — Regulatory Framework
29.3.1.3Germany — Competitive Scenario
29.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
29.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
29.3.1.6Germany Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
29.3.1.7Germany Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
29.3.1.8Germany Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
29.3.1.9Germany Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
29.3.1.10Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
29.3.1.11Germany Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
29.3.1.12Germany Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
29.3.1.13Germany Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
29.3.1.14Germany Market Overview, By Application, 2020–2034, Revenue (USD Billion)
29.3.1.15Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
29.3.2France
29.3.3Italy
29.3.4Spain
29.3.5UK
29.3.6Nordic Countries
29.3.7Benelux Union
29.3.8Rest of Europe
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 29.3.1 (Germany).
Chapter 30.Asia Pacific RNA Editing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
30.1Overview, 2020–2034
30.2Size and Projections, 2020–2034, Revenue (USD Billion)
30.2.1By Technology, 2020–2034
30.2.2By Edit Type, 2020–2034
30.2.3By Delivery Method, 2020–2034
30.2.4By Offering, 2020–2034
30.2.5By Therapeutic Area, 2020–2034
30.2.6By Target Mechanism, 2020–2034
30.2.7By Development Stage, 2020–2034
30.2.8By Route of Administration, 2020–2034
30.2.9By Application, 2020–2034
30.2.10By End User, 2020–2034
30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
30.3.1India
30.3.1.1India — Key Country Dynamics
30.3.1.2India — Regulatory Framework
30.3.1.3India — Competitive Scenario
30.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
30.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
30.3.1.6India Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
30.3.1.7India Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
30.3.1.8India Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
30.3.1.9India Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
30.3.1.10India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
30.3.1.11India Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
30.3.1.12India Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
30.3.1.13India Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
30.3.1.14India Market Overview, By Application, 2020–2034, Revenue (USD Billion)
30.3.1.15India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
30.3.2Australia
30.3.3China
30.3.4China (Taiwan)
30.3.5Japan
30.3.6South Korea
30.3.7Southeast Asia
30.3.8Indonesia
30.3.9Thailand
30.3.10Malaysia
30.3.11Singapore
30.3.12Rest of Asia Pacific
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 30.3.1 (India).
Chapter 31.Latin America RNA Editing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
31.1Overview, 2020–2034
31.2Size and Projections, 2020–2034, Revenue (USD Billion)
31.2.1By Technology, 2020–2034
31.2.2By Edit Type, 2020–2034
31.2.3By Delivery Method, 2020–2034
31.2.4By Offering, 2020–2034
31.2.5By Therapeutic Area, 2020–2034
31.2.6By Target Mechanism, 2020–2034
31.2.7By Development Stage, 2020–2034
31.2.8By Route of Administration, 2020–2034
31.2.9By Application, 2020–2034
31.2.10By End User, 2020–2034
31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
31.3.1Brazil
31.3.1.1Brazil — Key Country Dynamics
31.3.1.2Brazil — Regulatory Framework
31.3.1.3Brazil — Competitive Scenario
31.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
31.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
31.3.1.6Brazil Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
31.3.1.7Brazil Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
31.3.1.8Brazil Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
31.3.1.9Brazil Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
31.3.1.10Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
31.3.1.11Brazil Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
31.3.1.12Brazil Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
31.3.1.13Brazil Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
31.3.1.14Brazil Market Overview, By Application, 2020–2034, Revenue (USD Billion)
31.3.1.15Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
31.3.2Argentina
31.3.3Rest of Latin America
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 31.3.1 (Brazil).
Chapter 32.Middle East and Africa RNA Editing Market Deep-Dive, 2020–2034, Revenue (USD Billion)
32.1Overview, 2020–2034
32.2Size and Projections, 2020–2034, Revenue (USD Billion)
32.2.1By Technology, 2020–2034
32.2.2By Edit Type, 2020–2034
32.2.3By Delivery Method, 2020–2034
32.2.4By Offering, 2020–2034
32.2.5By Therapeutic Area, 2020–2034
32.2.6By Target Mechanism, 2020–2034
32.2.7By Development Stage, 2020–2034
32.2.8By Route of Administration, 2020–2034
32.2.9By Application, 2020–2034
32.2.10By End User, 2020–2034
32.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
32.3.1GCC
32.3.1.1GCC — Key Country Dynamics
32.3.1.2GCC — Regulatory Framework
32.3.1.3GCC — Competitive Scenario
32.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
32.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
32.3.1.6GCC Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
32.3.1.7GCC Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
32.3.1.8GCC Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
32.3.1.9GCC Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
32.3.1.10GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
32.3.1.11GCC Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
32.3.1.12GCC Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
32.3.1.13GCC Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
32.3.1.14GCC Market Overview, By Application, 2020–2034, Revenue (USD Billion)
32.3.1.15GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
32.3.2Egypt
32.3.3South Africa
32.3.4Rest of the Middle East & Africa
Note: the data representation for every other item above adheres to the same structure and format demonstrated in section 32.3.1 (GCC).
Chapter 33.Application / Use-Case Analysis
Chapter 34.Vendor Capability Scorecard
Chapter 35.Scenario Forecasts
35.1Bull-case Trajectory
35.2Base-case Trajectory
35.3Bear-case Trajectory
Chapter 36.Top 10 Key Clients of Top 10 Players
Chapter 37.Top 10 Suppliers
Chapter 38.Competitive Landscape
38.1Wave Life Sciences Ltd.
38.2Korro Bio, Inc.
38.3ProQR Therapeutics N.V.
38.4Shape Therapeutics Inc.
38.5Ascidian Therapeutics, Inc.
38.6AIRNA Corporation
38.7Roche Holding AG
38.8Ionis Pharmaceuticals, Inc.
38.9Arrowhead Pharmaceuticals, Inc.
38.10Beam Therapeutics Inc.
38.11Editas Medicine, Inc.
38.12Intellia Therapeutics, Inc.
38.13CRISPR Therapeutics AG
38.14Prime Medicine, Inc.
38.15Sarepta Therapeutics, Inc.
38.16Thermo Fisher Scientific Inc.
38.17Merck KGaA
38.18Danaher Corporation
38.19Agilent Technologies, Inc.
38.20Integrated DNA Technologies, Inc.
38.21Twist Bioscience Corporation
38.22GenScript Biotech Corporation
38.23Eli Lilly and Company
38.24Novo Nordisk A/S
38.25Skyhawk Therapeutics, Inc.
38.26Rznomics Inc.
38.27Ethris GmbH
38.28Bio-Techne Corporation
Chapter 39.Partnerships & M&A
Chapter 40.Key Vendor Analysis
40.1Wave Life Sciences Ltd.
40.2Korro Bio, Inc.
40.3ProQR Therapeutics N.V.
40.4Shape Therapeutics Inc.
40.5Ascidian Therapeutics, Inc.
40.6AIRNA Corporation
40.7Roche Holding AG
40.8Ionis Pharmaceuticals, Inc.
40.9Arrowhead Pharmaceuticals, Inc.
40.10Beam Therapeutics Inc.
40.11Editas Medicine, Inc.
40.12Intellia Therapeutics, Inc.
40.13CRISPR Therapeutics AG
40.14Prime Medicine, Inc.
40.15Sarepta Therapeutics, Inc.
40.16Thermo Fisher Scientific Inc.
40.17Merck KGaA
40.18Danaher Corporation
40.19Agilent Technologies, Inc.
40.20Integrated DNA Technologies, Inc.
40.21Twist Bioscience Corporation
40.22GenScript Biotech Corporation
40.23Eli Lilly and Company
40.24Novo Nordisk A/S
40.25Skyhawk Therapeutics, Inc.
40.26Rznomics Inc.
40.27Ethris GmbH
40.28Bio-Techne Corporation
Chapter 41.Marketing Strategy Analysis, Distributors & Traders
Chapter 42.Outlook of the Market
Chapter 43.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
Figure 2.1Top 3 Trends to Watch
Figure 2.4Top Investment Pockets
Figure 2.4.1Market Attractiveness Analysis, By Technology
Figure 2.4.2Market Attractiveness Analysis, By Edit Type
Figure 2.4.3Market Attractiveness Analysis, By Delivery Method
Figure 2.4.4Market Attractiveness Analysis, By Offering
Figure 2.4.5Market Attractiveness Analysis, By Therapeutic Area
Figure 2.4.6Market Attractiveness Analysis, By Target Mechanism
Figure 2.4.7Market Attractiveness Analysis, By Development Stage
Figure 2.4.8Market Attractiveness Analysis, By Route of Administration
Figure 2.4.9Market Attractiveness Analysis, By Application
Figure 2.4.10Market Attractiveness Analysis, By End User
Figure 2.5Key Market Participants — Intensity Mapping
Figure 4.2.2.2Data Triangulation
Figure 4.3Flow Of Methodology
Figure 4.4Top-Down / Bottom-Up Approach
Figure 6.1.2Product Differentiation and Positioning Logic
Figure 16.3Global RNA Editing Market Share, By Technology (%)
Figure 17.3Global RNA Editing Market Share, By Edit Type (%)
Figure 18.3Global RNA Editing Market Share, By Delivery Method (%)
Figure 19.3Global RNA Editing Market Share, By Offering (%)
Figure 20.3Global RNA Editing Market Share, By Therapeutic Area (%)
Figure 21.3Global RNA Editing Market Share, By Target Mechanism (%)
Figure 22.3Global RNA Editing Market Share, By Development Stage (%)
Figure 23.3Global RNA Editing Market Share, By Route of Administration (%)
Figure 24.3Global RNA Editing Market Share, By Application (%)
Figure 25.3Global RNA Editing Market Share, By End User (%)
Figure 27.2Share, By Geography, 2020–2034 (%)
Figure 27.3Share, By Geography Analysis, 2025, Market Share and CAGR
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Table 1.3RNA Editing Comparison By Segments
Table 4.1.2Market Size Estimation
Table 15.1Global RNA Editing Market Size — Total
Table 15.2Market Size, by Segment (By Technology, By Edit Type, By Delivery Method, By Offering, By Therapeutic Area, By Target Mechanism, By Development Stage, By Route of Administration, By Application, By End User)
Table 16.2Global RNA Editing Market Size, By Technology, 2020–2034, Revenue (USD Billion)
Table 16.3.1.1Market Size, By ADAR-based RNA Editing, 2020–2034, Revenue (USD Billion)
Table 16.3.1.2ADAR-based RNA Editing Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 16.3.1.3ADAR-based RNA Editing Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 16.3.1.4ADAR-based RNA Editing Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 16.3.1.5ADAR-based RNA Editing Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 16.3.1.6ADAR-based RNA Editing Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 16.3.1.7ADAR-based RNA Editing Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 16.3.1.8ADAR-based RNA Editing Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 16.3.1.9ADAR-based RNA Editing Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 16.3.1.10ADAR-based RNA Editing Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 17.2Global RNA Editing Market Size, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 17.3.1.1Market Size, By Adenosine-to-Inosine (A-to-I), 2020–2034, Revenue (USD Billion)
Table 17.3.1.2Adenosine-to-Inosine (A-to-I) Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 17.3.1.3Adenosine-to-Inosine (A-to-I) Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 17.3.1.4Adenosine-to-Inosine (A-to-I) Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 17.3.1.5Adenosine-to-Inosine (A-to-I) Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 17.3.1.6Adenosine-to-Inosine (A-to-I) Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 17.3.1.7Adenosine-to-Inosine (A-to-I) Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 17.3.1.8Adenosine-to-Inosine (A-to-I) Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 17.3.1.9Adenosine-to-Inosine (A-to-I) Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 17.3.1.10Adenosine-to-Inosine (A-to-I) Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 18.2Global RNA Editing Market Size, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 18.3.1.1Market Size, By Lipid Nanoparticles, 2020–2034, Revenue (USD Billion)
Table 18.3.1.2Lipid Nanoparticles Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 18.3.1.3Lipid Nanoparticles Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 18.3.1.4Lipid Nanoparticles Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 18.3.1.5Lipid Nanoparticles Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 18.3.1.6Lipid Nanoparticles Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 18.3.1.7Lipid Nanoparticles Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 18.3.1.8Lipid Nanoparticles Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 18.3.1.9Lipid Nanoparticles Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 18.3.1.10Lipid Nanoparticles Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 19.2Global RNA Editing Market Size, By Offering, 2020–2034, Revenue (USD Billion)
Table 19.3.1.1Market Size, By Therapeutic Candidates and Programs, 2020–2034, Revenue (USD Billion)
Table 19.3.1.2Therapeutic Candidates and Programs Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 19.3.1.3Therapeutic Candidates and Programs Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 19.3.1.4Therapeutic Candidates and Programs Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 19.3.1.5Therapeutic Candidates and Programs Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 19.3.1.6Therapeutic Candidates and Programs Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 19.3.1.7Therapeutic Candidates and Programs Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 19.3.1.8Therapeutic Candidates and Programs Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 19.3.1.9Therapeutic Candidates and Programs Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 19.3.1.10Therapeutic Candidates and Programs Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 20.2Global RNA Editing Market Size, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 20.3.1.1Market Size, By Rare Genetic Disorders, 2020–2034, Revenue (USD Billion)
Table 20.3.1.2Rare Genetic Disorders Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 20.3.1.3Rare Genetic Disorders Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 20.3.1.4Rare Genetic Disorders Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 20.3.1.5Rare Genetic Disorders Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 20.3.1.6Rare Genetic Disorders Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 20.3.1.7Rare Genetic Disorders Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 20.3.1.8Rare Genetic Disorders Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 20.3.1.9Rare Genetic Disorders Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 20.3.1.10Rare Genetic Disorders Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 21.2Global RNA Editing Market Size, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 21.3.1.1Market Size, By Correction of Pathogenic Point Mutations, 2020–2034, Revenue (USD Billion)
Table 21.3.1.2Correction of Pathogenic Point Mutations Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 21.3.1.3Correction of Pathogenic Point Mutations Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 21.3.1.4Correction of Pathogenic Point Mutations Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 21.3.1.5Correction of Pathogenic Point Mutations Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 21.3.1.6Correction of Pathogenic Point Mutations Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 21.3.1.7Correction of Pathogenic Point Mutations Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 21.3.1.8Correction of Pathogenic Point Mutations Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 21.3.1.9Correction of Pathogenic Point Mutations Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 21.3.1.10Correction of Pathogenic Point Mutations Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 22.2Global RNA Editing Market Size, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 22.3.1.1Market Size, By Discovery and Research, 2020–2034, Revenue (USD Billion)
Table 22.3.1.2Discovery and Research Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 22.3.1.3Discovery and Research Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 22.3.1.4Discovery and Research Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 22.3.1.5Discovery and Research Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 22.3.1.6Discovery and Research Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 22.3.1.7Discovery and Research Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 22.3.1.8Discovery and Research Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 22.3.1.9Discovery and Research Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 22.3.1.10Discovery and Research Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 23.2Global RNA Editing Market Size, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 23.3.1.1Market Size, By Intravenous, 2020–2034, Revenue (USD Billion)
Table 23.3.1.2Intravenous Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 23.3.1.3Intravenous Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 23.3.1.4Intravenous Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 23.3.1.5Intravenous Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 23.3.1.6Intravenous Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 23.3.1.7Intravenous Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 23.3.1.8Intravenous Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 23.3.1.9Intravenous Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 23.3.1.10Intravenous Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 24.2Global RNA Editing Market Size, By Application, 2020–2034, Revenue (USD Billion)
Table 24.3.1.1Market Size, By Therapeutics Development, 2020–2034, Revenue (USD Billion)
Table 24.3.1.2Therapeutics Development Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 24.3.1.3Therapeutics Development Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 24.3.1.4Therapeutics Development Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 24.3.1.5Therapeutics Development Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 24.3.1.6Therapeutics Development Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 24.3.1.7Therapeutics Development Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 24.3.1.8Therapeutics Development Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 24.3.1.9Therapeutics Development Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 24.3.1.10Therapeutics Development Size and Projections, By End User, 2020–2034, Revenue (USD Billion)
Table 25.2Global RNA Editing Market Size, By End User, 2020–2034, Revenue (USD Billion)
Table 25.3.1.1Market Size, By Biotechnology Companies, 2020–2034, Revenue (USD Billion)
Table 25.3.1.2Biotechnology Companies Size and Projections, By Technology, 2020–2034, Revenue (USD Billion)
Table 25.3.1.3Biotechnology Companies Size and Projections, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 25.3.1.4Biotechnology Companies Size and Projections, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 25.3.1.5Biotechnology Companies Size and Projections, By Offering, 2020–2034, Revenue (USD Billion)
Table 25.3.1.6Biotechnology Companies Size and Projections, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 25.3.1.7Biotechnology Companies Size and Projections, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 25.3.1.8Biotechnology Companies Size and Projections, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 25.3.1.9Biotechnology Companies Size and Projections, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 25.3.1.10Biotechnology Companies Size and Projections, By Application, 2020–2034, Revenue (USD Billion)
Table 27.1Revenue, By Geography, 2020–2034, Revenue (USD Billion)
Table 27.4Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 28.1Overview, 2020–2034
Table 28.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.2.1By Technology, 2020–2034
Table 28.2.2By Edit Type, 2020–2034
Table 28.2.3By Delivery Method, 2020–2034
Table 28.2.4By Offering, 2020–2034
Table 28.2.5By Therapeutic Area, 2020–2034
Table 28.2.6By Target Mechanism, 2020–2034
Table 28.2.7By Development Stage, 2020–2034
Table 28.2.8By Route of Administration, 2020–2034
Table 28.2.9By Application, 2020–2034
Table 28.2.10By End User, 2020–2034
Table 28.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 28.3.1.4US — Market Overview, 2020–2034, Revenue (USD Billion)
Table 28.3.1.5US — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 28.3.1.6US Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 28.3.1.7US Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 28.3.1.8US Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 28.3.1.9US Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
Table 28.3.1.10US Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 28.3.1.11US Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 28.3.1.12US Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 28.3.1.13US Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 28.3.1.14US Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 28.3.1.15US Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 29.1Overview, 2020–2034
Table 29.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.2.1By Technology, 2020–2034
Table 29.2.2By Edit Type, 2020–2034
Table 29.2.3By Delivery Method, 2020–2034
Table 29.2.4By Offering, 2020–2034
Table 29.2.5By Therapeutic Area, 2020–2034
Table 29.2.6By Target Mechanism, 2020–2034
Table 29.2.7By Development Stage, 2020–2034
Table 29.2.8By Route of Administration, 2020–2034
Table 29.2.9By Application, 2020–2034
Table 29.2.10By End User, 2020–2034
Table 29.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 29.3.1.4Germany — Market Overview, 2020–2034, Revenue (USD Billion)
Table 29.3.1.5Germany — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 29.3.1.6Germany Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 29.3.1.7Germany Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 29.3.1.8Germany Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 29.3.1.9Germany Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
Table 29.3.1.10Germany Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 29.3.1.11Germany Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 29.3.1.12Germany Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 29.3.1.13Germany Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 29.3.1.14Germany Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 29.3.1.15Germany Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 30.1Overview, 2020–2034
Table 30.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.2.1By Technology, 2020–2034
Table 30.2.2By Edit Type, 2020–2034
Table 30.2.3By Delivery Method, 2020–2034
Table 30.2.4By Offering, 2020–2034
Table 30.2.5By Therapeutic Area, 2020–2034
Table 30.2.6By Target Mechanism, 2020–2034
Table 30.2.7By Development Stage, 2020–2034
Table 30.2.8By Route of Administration, 2020–2034
Table 30.2.9By Application, 2020–2034
Table 30.2.10By End User, 2020–2034
Table 30.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 30.3.1.4India — Market Overview, 2020–2034, Revenue (USD Billion)
Table 30.3.1.5India — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 30.3.1.6India Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 30.3.1.7India Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 30.3.1.8India Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 30.3.1.9India Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
Table 30.3.1.10India Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 30.3.1.11India Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 30.3.1.12India Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 30.3.1.13India Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 30.3.1.14India Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 30.3.1.15India Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 31.1Overview, 2020–2034
Table 31.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.2.1By Technology, 2020–2034
Table 31.2.2By Edit Type, 2020–2034
Table 31.2.3By Delivery Method, 2020–2034
Table 31.2.4By Offering, 2020–2034
Table 31.2.5By Therapeutic Area, 2020–2034
Table 31.2.6By Target Mechanism, 2020–2034
Table 31.2.7By Development Stage, 2020–2034
Table 31.2.8By Route of Administration, 2020–2034
Table 31.2.9By Application, 2020–2034
Table 31.2.10By End User, 2020–2034
Table 31.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 31.3.1.4Brazil — Market Overview, 2020–2034, Revenue (USD Billion)
Table 31.3.1.5Brazil — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 31.3.1.6Brazil Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 31.3.1.7Brazil Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 31.3.1.8Brazil Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 31.3.1.9Brazil Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
Table 31.3.1.10Brazil Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 31.3.1.11Brazil Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 31.3.1.12Brazil Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 31.3.1.13Brazil Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 31.3.1.14Brazil Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 31.3.1.15Brazil Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Table 32.1Overview, 2020–2034
Table 32.2Size and Projections, 2020–2034, Revenue (USD Billion)
Table 32.2.1By Technology, 2020–2034
Table 32.2.2By Edit Type, 2020–2034
Table 32.2.3By Delivery Method, 2020–2034
Table 32.2.4By Offering, 2020–2034
Table 32.2.5By Therapeutic Area, 2020–2034
Table 32.2.6By Target Mechanism, 2020–2034
Table 32.2.7By Development Stage, 2020–2034
Table 32.2.8By Route of Administration, 2020–2034
Table 32.2.9By Application, 2020–2034
Table 32.2.10By End User, 2020–2034
Table 32.3Size and Projections, By Countries, 2020–2034, Revenue (USD Billion)
Table 32.3.1.4GCC — Market Overview, 2020–2034, Revenue (USD Billion)
Table 32.3.1.5GCC — Market Size and Projections, 2020–2034, Revenue (USD Billion)
Table 32.3.1.6GCC Market Overview, By Technology, 2020–2034, Revenue (USD Billion)
Table 32.3.1.7GCC Market Overview, By Edit Type, 2020–2034, Revenue (USD Billion)
Table 32.3.1.8GCC Market Overview, By Delivery Method, 2020–2034, Revenue (USD Billion)
Table 32.3.1.9GCC Market Overview, By Offering, 2020–2034, Revenue (USD Billion)
Table 32.3.1.10GCC Market Overview, By Therapeutic Area, 2020–2034, Revenue (USD Billion)
Table 32.3.1.11GCC Market Overview, By Target Mechanism, 2020–2034, Revenue (USD Billion)
Table 32.3.1.12GCC Market Overview, By Development Stage, 2020–2034, Revenue (USD Billion)
Table 32.3.1.13GCC Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Table 32.3.1.14GCC Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Table 32.3.1.15GCC Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Scope
Questions This Report Answers
6 questions01
What is the market size and growth rate, globally and by region?
02
How is the market segmented, and which segments lead?
03
Which regions and countries are covered, and how do they compare?
04
What are the key drivers, restraints, opportunities and challenges?
05
Who are the leading companies operating in this market?
06
What trends are expected to shape the market through the forecast period?
Questions
Frequently Asked Questions
01What is the RNA Editing Market projected to reach?
USD 9.25 USD Billion by 2034, CAGR 19%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 50% of global revenue through 2034.
05Which segment leads the market?
ADAR-based RNA Editing is the largest line by technology, at 40% of revenue in 2025.
06Who are the key companies profiled?
Wave Life Sciences Ltd., Korro Bio, Inc., ProQR Therapeutics N.V., Shape Therapeutics Inc., Ascidian Therapeutics, Inc., AIRNA Corporation, Roche Holding AG, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Beam Therapeutics Inc., Editas Medicine, Inc., Intellia Therapeutics, Inc., CRISPR Therapeutics AG, Prime Medicine, Inc., Sarepta Therapeutics, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies, Inc., Integrated DNA Technologies, Inc., Twist Bioscience Corporation, GenScript Biotech Corporation, Eli Lilly and Company, Novo Nordisk A/S, Skyhawk Therapeutics, Inc., Rznomics Inc., Ethris GmbH, Bio-Techne Corporation. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
425+
Dedicated research analysts
1,200+
Reports published
Why CDI
Why choose CDI
Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.
Explore
Related Reports
Pharmaceuticals & Biotech
Biologics Market
USD 1051 Bn by 2034, CAGR 8.68%
Pharmaceuticals & Biotech
Clinical Trial Supplies Market
USD 9.96 Bn by 2034, CAGR 9%
Pharmaceuticals & Biotech
Cell Culture Market
USD 73.8 Bn by 2034, CAGR 11%
Pharmaceuticals & Biotech
Continuous Bioprocessing Market
USD 1220 Mn by 2034, CAGR 14.33%
Pharmaceuticals & Biotech
Peptide Therapeutics Market
USD 291.5 Bn by 2034, CAGR 8.93%
Pharmaceuticals & Biotech
Next Generation Sequencing Market
USD 49.09 Bn by 2034, CAGR 14.5%